Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act
United States115th CongressHR-5605House of Representatives
Updated: Jun 20, 2018
Summary
Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act (Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures. Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants. (Sec. 3) The bill also requires prescriptions for controlled substances that are covered under the Medicare prescription drug benefit or Medicare Advantage prescription drug plans to be transmitted via electronic prescription programs. The CMS may waive such requirements under specified circumstances.
Bill texts
Timeline
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)
House of Representatives
Motion to reconsider laid on the table Agreed to without objection.
House of Representatives
The title of the measure was amended. Agreed to without objection.
House of Representatives
Received in the Senate and Read twice and referred to the Committee on Finance.
Senate